Marshall Wace North America L.P. - INTRA CELLULAR THERAPIES INC ownership

INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 177 filers reported holding INTRA CELLULAR THERAPIES INC in Q3 2020. The put-call ratio across all filers is 0.76 and the average weighting 0.1%.

Quarter-by-quarter ownership
Marshall Wace North America L.P. ownership history of INTRA CELLULAR THERAPIES INC
ValueSharesWeighting
Q4 2020$15,274,000
+23.9%
480,3010.0%0.07%
-11.4%
Q3 2020$12,325,000
+813.0%
480,301
+469.4%
0.08%
+777.8%
Q3 2017$1,350,00084,3580.01%
Other shareholders
INTRA CELLULAR THERAPIES INC shareholders Q3 2020
NameSharesValueWeighting ↓
Sarissa Capital Management LP 640,000$25,626,0006.33%
Redmile Group, LLC 1,322,592$52,957,0004.01%
SENZAR ASSET MANAGEMENT, LLC 556,224$22,271,209,0003.24%
RA Capital Management 314,349$12,587,0001.81%
WALL STREET ASSOCIATES 205,657$8,235,0001.58%
Parametrica Management Ltd 5,400$216,0001.36%
Rhenman & Partners Asset Management AB 165,000$6,607,0001.05%
EAM Investors, LLC 95,168$3,811,0000.60%
Rock Springs Capital Management LP 180,000$7,207,0000.58%
WASATCH ADVISORS LP 1,085,973$43,482,0000.58%
View complete list of INTRA CELLULAR THERAPIES INC shareholders